ALIVUS
Alivus Life Sciences Limited
Each stock's 10,000-path forecast, rendered as light.
Alivus Life Sciences Limited (ALIVUS) Stock Analysis & Case Study
Is ALIVUS a good buy? The data-driven verdict.
Alivus Life Sciences Limited (ALIVUS) trades at ₹1,330,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Alivus Life Sciences Limited (ALIVUS) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 46.4× earnings, ROE of 2.0%, a 54% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
ALIVUS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How ALIVUS ranks against the 2,373 companies in our screener
- ALIVUS's market cap of 16,326 Cr ranks in the 82nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ALIVUS's book value of ₹0 ranks in the bottom 4% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ALIVUS's promoter holding of 74.9% ranks in the 92nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ALIVUS's 3-year profit (PAT) growth of 27.0% ranks in the 66th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ALIVUS's 3-year revenue growth of 27.0% ranks in the 82nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
We do not hold a debt-to-equity ratio figure for ALIVUS, as of 9 Aug 2026, so it is not ranked here.
Is ALIVUS overvalued? ALIVUS P/E vs peers
ALIVUS trades at 46.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
ALIVUS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 4.9y of ALIVUS history (12%/yr drift, 38%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ALIVUS 2027 | ₹845 | ₹1,376 | ₹2,242 | +4% |
| ALIVUS 2028 | ₹710 | ₹1,425 | ₹2,861 | +7% |
| ALIVUS 2029 | ₹642 | ₹1,475 | ₹3,386 | +11% |
| ALIVUS 2030 | ₹582 | ₹1,527 | ₹4,002 | +15% |
| ALIVUS 2031 | ₹537 | ₹1,580 | ₹4,652 | +19% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ALIVUS goes up, or doubles?
The bull case for ALIVUS
- Alivus Life Sciences Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,386.
The bear case & risks
- ALIVUS's P/E of 46.4x is lower than 29% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 3500.0× price-to-book means most of the value is intangible/expectations, not assets on the books.
- ALIVUS's return on equity of 2.0% ranks in the 20th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹642.
ALIVUS volatility & expected range, how bumpy is the ride?
Over the last 4.9 years ALIVUS compounded at 12%/year with annualized volatility of 38%. That volatility implies a 1-year 80% range of ₹845-₹2,242, the honest backbone behind any single price target.
ALIVUS price forecast, the full 60-month probability fan
ALIVUS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ALIVUS hits common targets within the simulated horizon?
Full multi-horizon detail on the ALIVUS price target & forecast page.
ALIVUS Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. ALIVUS scores 5/8, mixed financial health.
ALIVUS MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy ALIVUS with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 30.99% | 3.2× |
| Groww | 31.09% | 3.2× |
| Dhan | 30.99% | 3.2× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 31.09% | 3.2× |
| PocketfulCHEAPEST | 30.01% | 3.3× |
| Anand Rathi | 30.99% | 3.2× |
| Bajaj Broking | 34.00% | 2.9× |
| Share India | 30.38% | 3.3× |
Compare every broker on the ALIVUS MTF page.
About Alivus Life Sciences Limited: sector, index & market-cap context
Alivus Life Sciences Limited (ALIVUS) is a small-cap NSE-listed company, with a market capitalisation of ₹16,326 Cr. See more stocks on our screener.
How the ALIVUS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Alivus Life Sciences Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ALIVUS analysis, FAQs
Is Alivus Life Sciences Limited (ALIVUS) a good buy?
On the numbers, Alivus Life Sciences Limited (ALIVUS) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 46.4× earnings, ROE of 2.0%, a 54% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ALIVUS overvalued or undervalued?
ALIVUS trades at 46.4× earnings, expensive versus the ~22× long-run Nifty average.
What is the ALIVUS share price target for 2031?
ALIVUS's probability-weighted 2031 median target is ₹1,580, with an 80% range of ₹537-₹4,652 (10,000-path Monte-Carlo).
What is the probability ALIVUS doubles in 5 years?
The modelled probability of ALIVUS reaching ₹2,660 (2×) within 5 years is 27%.
What is the bull case for ALIVUS?
Alivus Life Sciences Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in ALIVUS?
ALIVUS's P/E of 46.4x is lower than 29% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 3500.0× price-to-book means most of the value is intangible/expectations, not assets on the books. ALIVUS's return on equity of 2.0% ranks in the 20th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.